CalciMedica (NASDAQ:CALC) Stock Rating Reaffirmed by HC Wainwright

CalciMedica (NASDAQ:CALCGet Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $20.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 395.05% from the company’s previous close.

Separately, Jonestrading assumed coverage on CalciMedica in a research report on Friday, February 16th. They set a “buy” rating and a $22.00 price target for the company.

Check Out Our Latest Stock Report on CALC

CalciMedica Price Performance

CALC stock opened at $4.04 on Monday. CalciMedica has a 12 month low of $1.00 and a 12 month high of $8.59. The firm has a market capitalization of $22.95 million, a PE ratio of -0.16 and a beta of 1.61. The company’s 50 day simple moving average is $4.74 and its 200-day simple moving average is $3.64.

Insider Transactions at CalciMedica

In related news, major shareholder Sanderling Venture Partners Vi purchased 243,356 shares of the business’s stock in a transaction dated Tuesday, January 23rd. The stock was bought at an average cost of $3.70 per share, with a total value of $900,417.20. Following the completion of the acquisition, the insider now directly owns 946,744 shares in the company, valued at approximately $3,502,952.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other CalciMedica news, Director Fred A. Middleton bought 679,384 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was purchased at an average cost of $3.70 per share, for a total transaction of $2,513,720.80. Following the completion of the purchase, the director now owns 946,744 shares of the company’s stock, valued at approximately $3,502,952.80. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Sanderling Venture Partners Vi bought 243,356 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was acquired at an average price of $3.70 per share, with a total value of $900,417.20. Following the completion of the purchase, the insider now directly owns 946,744 shares of the company’s stock, valued at approximately $3,502,952.80. The disclosure for this purchase can be found here. Insiders purchased a total of 923,486 shares of company stock valued at $3,417,047 over the last three months. 53.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CalciMedica

Several institutional investors have recently added to or reduced their stakes in the business. Meritage Portfolio Management increased its stake in CalciMedica by 360.0% in the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock valued at $132,000 after purchasing an additional 36,000 shares during the last quarter. BML Capital Management LLC increased its stake in CalciMedica by 63.8% in the fourth quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock valued at $416,000 after purchasing an additional 56,643 shares during the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in CalciMedica in the third quarter valued at $432,000.

CalciMedica Company Profile

(Get Free Report)

CalciMedica, Inc, a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.

Recommended Stories

Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.